Abbott’s AdviseDx SARS-CoV-2 IgM Test Receives the US FDA’s EUA for COVID-19

 Abbott’s AdviseDx SARS-CoV-2 IgM Test Receives the US FDA’s EUA for COVID-19

Abbott’s AdviseDx SARS-CoV-2 IgM Test Receives the US FDA’s EUA for COVID-19

Shots:

  • Abbott has received the US FDA’s EUA for AdviseDx SARS-CoV-2 IgM lab-based serology test for use on the ARCHITECT and Alinity platforms
  • Till now, Abbott has received EUA for its seven tests, including molecular tests, a rapid antigen test and, an IgG Ab test for COVID-19
  • The IgM test demonstrated 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset. The test will give a more complete picture of where patients are in their recovery

    Click here ­to­ read full press release/ article | Ref: Abbott | Image: Medical Device and Diagnostic Industry

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post